VAXART INC WKN: A2JD8X ISIN: US92243A2006 Kürzel: VXRT Forum: Aktien Thema: Hauptdiskussion

Nur meine Meinung

Es waren nicht so Top news leider….

Zum zocken wird es schon passen, ich bin mir aber nicht sicher, dass es was übrig bleibt 🙈

Hoffentlich ab 15.30 sobald die Amis loslegen

Ist aber noch nichts passiert, Hans 😉

Heeeee

October 7, 2021 4:13 PM EDT New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

Moin, natürlich Du! Wer sonst? 👍

Wer hat sich an der Nase immer gerieben und danach ist was passiert ?

🤔🤔🤔🤔

Good news for some companies often means bad news for others. That's what we're seeing Friday as the stocks of several COVID-19 vaccine makers sank following the announcement by Merck (NYSE: MRK) and Ridgeback Biotherapeutics of positive results from a late-stage study of an oral COVID-19 treatment. Shares of Pfizer (NYSE: PFE) were down by 1.6% as of 11:20 a.m. EDT after having declined by as much as 3.1% earlier in the session. Pfizer's COVID vaccine partner, BioNTech (NASDAQ: BNTX), fared even worse, with its stock sliding by 11.9%.A couple of companies that have COVID-19 vaccine candidates that aren't on the market yet also felt the sting of the news from Merck and Ridgeback. Novavax (NASDAQ: NVAX) stock was trading 17% lower, while shares of Vaxart (NASDAQ: VXRT) dropped by 12.3%

Hier nochmal eine kurze Zsfassung wieso die (oder einige davon) Biontechs etwas straucheln..

So langsam aber sicher sollten diesen Herbst mal viel versprechende Ergebnisse vorgelegt werden ...

Dr. Johnson's Presentation Title: A room temperature-stable, tablet-based SARS-COV-2 oral vaccine candidate induces both antigen-specific mucosal IgA responses and CD8 T cell responses in humans Session Name: Breakout Session 09 - Vaccines against SARS-CoV-2 Date: 10/5/2021 Time: 06:00:00 AM-06:15:00 AM Eastern Presentation Duration: 15 minutes including Q&A

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress. Dr. Johnson will provide an update on the development of Vaxart's COVID-19 oral vaccine candidate.